HM Payson & Co. Has $36.73 Million Position in Danaher Co. (NYSE:DHR)

HM Payson & Co. lessened its position in shares of Danaher Co. (NYSE:DHR) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 132,098 shares of the conglomerate’s stock after selling 4,708 shares during the quarter. HM Payson & Co.’s holdings in Danaher were worth $36,726,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher in the 2nd quarter valued at approximately $25,000. nVerses Capital LLC acquired a new position in shares of Danaher during the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Danaher during the 2nd quarter worth approximately $51,000. Financial Connections Group Inc. acquired a new position in shares of Danaher during the 2nd quarter worth approximately $51,000. Finally, Western Pacific Wealth Management LP acquired a new position in shares of Danaher during the 1st quarter worth approximately $55,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of DHR traded up $1.42 on Thursday, reaching $243.74. 189,512 shares of the company’s stock traded hands, compared to its average volume of 2,730,503. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The stock has a market cap of $180.54 billion, a PE ratio of 41.07, a PEG ratio of 4.49 and a beta of 0.83. The stock’s 50 day simple moving average is $267.83 and its two-hundred day simple moving average is $260.42. Danaher Co. has a 52-week low of $188.75 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the business posted $2.02 earnings per share. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. On average, analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Evercore ISI lifted their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Royal Bank of Canada reduced their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Robert W. Baird reduced their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. The Goldman Sachs Group boosted their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Finally, Raymond James reduced their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.